Debora Dumont
Director @ Enhanc3D Genomics
Debora Dumont is a seed investor at Enhanc3D Genomics focused on Biotechnology and Therapeutics. Debora Dumont is the Managing Partner & Co-founder at Bioqube Ventures. He attended Hasselt University in 2002.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Debora Dumont invests in
Stages Debora Dumont invests in
Countries Debora Dumont invests in
Investment Focus
Industry
- Biotechnology 3 (75%)
- Therapeutics 2 (50%)
- Life Science 1 (25%)
Stage
- Seed 2 (50%)
- Series A 1 (25%)
Country
- Belgium 1 (25%)
- United States 1 (25%)
- The Netherlands 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Spica Therapeutics
|
Spica Therapeutics is a biotech company to transform macrophage biology into breakthrough therapies for patients. | $11.4M / Seed / Jun 04, 2025 | |
Anavo Therapeutics
|
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications | $9.4M / Seed / May 02, 2023 | |
Enhanc3D Genomics
|
Enhanc3D Genomics is a spinout company from Babraham Institute. | $11.2M / Series A / Oct 20, 2022 | |
|
Anavo Therapeutics
|
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavois developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications | $24M / Seed / Apr 22, 2021 |
Co-Investors
Inkef
2 deals together
M Ventures
2 deals together
Taiho Ventures
2 deals together
Business Growth Fund
1 deal together
MRL Ventures Fund
1 deal together
Parkwalk Advisors
1 deal together
About Enhanc3D Genomics
Enhanc3D Genomics is a spinout company from Babraham Institute.
Enhanc3D Genomics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Debora Dumont
Director
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Debora Dumont invest in?
Debora Dumont invests primarily in Biotechnology, Therapeutics and Life Science startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Debora Dumont last invest?
The most recent investment recorded for Debora Dumont closed in Jun 2025. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
